Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Diabetes drug 'increases bladder cancer risk'

  • Comment

A commonly prescribed diabetes drug increases the risk of bladder cancer, research has found.

Patients who use pioglitazone, a drug for type 2 diabetes, every day for more than two years double their chances of developing the disease.

The medication for controlling blood sugar levels is known to increase the risk of heart failure, but the European Medicines Agency decided to keep it on the market.

Researchers based in Canada analysed the medical records of more than 115,000 people across the UK who were given the drug over an 11-year period and found there were up to 137 extra cases of bladder cancer per 100,000 person years.

The results, published in the online medical journal, show that 470 patients were diagnosed with bladder cancer during the average 4.6 years of follow-up, a rate of 89 per 100,000 person years. The rate in the general UK population aged at least 65 is 73 per 100,000 person years.

The analysis involved 376 cases, matched to 6,699 controls.

If patients had ever taken pioglitazone they were at an 83% increased risk of bladder cancer, which corresponds to 74 per 100,000 person years.

This increased to 88 per 100,000 person years for patients who had taken the drug for two years or more and 137 per 100,000 years for patients who had taken 28,000mg or more.

Pioglitazone is similar to another drug, rosiglitazone, which also increases the risk of heart failure but does not increase the chance of bladder cancer.




  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.